Pharmacokinetics and Pharmacodynamics of Antithymocyte Globulin in Pediatric Hematopoietic Stem-Cell Transplant Recipients: Preliminary Analysis  by Schechter, T. et al.
Poster Session I S305269
PHARMACOKINETICS AND PHARMACODYNAMICS OF ANTITHYMOCYTE
GLOBULIN IN PEDIATRIC HEMATOPOIETIC STEM-CELL TRANSPLANT RE-
CIPIENTS: PRELIMINARY ANALYSIS
Schechter, T.1, Ali, M.1, Naithani, R.1, Storek, J.2, Egeler, M.1,
Finkelstein, Y.3, Gassas, A.1, Doyle, J.1, Dupuis, L.L.1 1The Hospital
for Sick Children, Toronto, ON, Canada; 2University of Calgary and Al-
berta Health Services, Calgary, AB, Canada; 3The Hospital for Sick Chil-
dren, Toronto, ON, Canada
Introduction: Antithymocyte globulin (ATG) is increasingly being
used in allogeneic hematopoietic stem-cell transplantation (HSCT)
to prevent graft rejection mainly in the context of non-myeloablative
regimens and cord blood transplantation, and to prevent acute graft-
versus-host disease (GVHD). Data on the pharmacokinetics and
pharmacodynamics of ATG in pediatric HSCT are limited. The
aim of this study was to describe ATG disposition in children under-
going HSCT and to explore associations between pharmacokinetic
parameters and certain HSCT outcomes.
Methods: Rabbit ATG (Thymoglobulin,Genzyme) was given at
a dose of 2.5 mg/kg/day as a single daily dose for 3 days on day -3
to day -1. Blood samples for ATG concentration determination
were obtained at 0, +1, +4, +7, +14, +28, +60, +75 and +100 days
post-HSCT. ATG serum concentrations were analyzed using a vali-
dated immunoassay.
ATG pharmacokinetic parameters were estimated using a non-
compartmental model (Phoenix WinNonlin 6.0.0.1648). The rela-
tionship between HSCT outcomes (acute GVHD, chronic
GVHD, graft failure, EBV viremia, viral infection or viremia,
post-transplant lymphoproliferative disease (PTLD) and overall sur-
vival) and pharmacokinetic parameters was explored.
Results: 17 patients (median age: 6.2 yr: range: 0.5-13yr) partici-
pated. On average, 8 samples were obtained from each patient. Me-
dian time of follow-up was 13 months (range: 4 to 22 months). 2/15
children developed acuteGVHD; 3/17 had engraftment failure; 4/13
developed chronic GVHD; 4/17 had EBV reactivation; 12/17 had
a viral infection or viremia and 3/17 developed PTLD. 14 were alive
at the time of last follow-up.
Large inter-patient variability was observed in pharmacokinetic
parameters. (Table 1)MeanCmax was significantly lower in children
with acute GVHD (meanCmax: 4.126 0.968 vs 8.826 2.645mg/L;
p5 0.0086). A trend toward a higher Cmax in children with viral in-
fection/reactivation of any type was observed (8.796 2.680 vs 5.626
2.617 mg/L; p 5 0.0544).
Conclusion: Large inter-patient variability in ATG pharmacoki-
netic dispostion was observed in pediatric HSCT patients. Themax-
imum ATG concentration after the third dose (Cmax) is inversely
associated with acute GVHD. Data in a larger sample should be ob-
tained to correlate ATG pharmacokinetic disposition with HSCT
outcomes.
Table 1. Mean pharmacokinetic parameters in 17 children
Pharmacokinetic Parameter Mean ± SD RangeElimination rate constant (hr-1) 0.0039 ± 0.00141 0.0015 to 0.0068
Elimination half-life (hr) 204.9 ± 93.30 101.9 to 470.2
Maximum concentration (mg/L) 7.86 ± 2.979 3.43 to 13.62
Area under the curve (hr*mg/L) 1434 ± 740.8 419 to 2539
Clearance (L/hr) 0.044 ± 0.0254 0.011 to 0.103
Time to thymoglobulin
concentration < 0.001mg/L (days)
96.2 ± 27.93 48.6 to 135.6270
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We performed a retrospective analysis on the outcome of 135
transplants for primary immunodeficiency syndromes in Australia
andNewZealand Children’s Haematology OncologyGroup (ANZ-
CHOG) transplant centres between 1992 and 2008. The most
common conditions transplanted were Severe Combined Immuno-
deficiency (SCID) (48%), Wiskott-Aldrich Syndrome (WAS)
(20%), and Chronic Granulomatous Disease (CGD) (12%). Median
age at time of transplant was 1 year (range 0-15). Median follow up
was 72 months. Stem cell source was matched sibling in 25%, parent
in 30%, and unrelated donor in 45%. 55% of unrelated grafts were
cord blood, themajority having at least oneHLAmismatch. 57% re-
ceivedmyeloablative conditioning (MAC), 25% received reduced in-
tensity conditioning (RIC), and 17% had no conditioning. 48% had
in-vivo T-cell depletion using ATG or Campath, and 30% had ex-
vivo T-cell depletion. 18 patients failed to engraft, 15 engrafted fol-
lowing second transplant, 3 following third transplant, and 11 of the
18 remain long term survivors. Median time to neutrophil and plate-
let engraftment was 16 and 30 days respectively, with a cumulative
incidence (CI) at day +42 of 86% and 63% respectively. The CI of
aGVHD grade II-IV and III-IV at day +100 was 25% and 10% re-
spectively. CI of cGVHD at 1 year was 16%. Transplant related
mortality (TRM) was 10% at day +100, with infection, interstitial
pneumonitis and GVHD the most common primary cause of death.
5 year overall survival (OS) was 72% for the cohort. Disease specific
5 year OS were SCID 70%,WAS 81% and CGD 69%.Multivariate
analysis demonstrated having a transplant performed after 1998 sig-
nificantly decreased the risk of aGvHD, but did not impact on overall
survival. In contrast, development of interstitial pneumonitis, CMV
infection/viraemia, aGVHD, and use of a mismatched family donor
were independent variables that significantly decreasedOS. Of inter-
est, type of conditioning, GVHD prophylaxis, and T cell depletion
did not significantly impact OS. In conclusion, this large series sup-
ports the use of transplantation as curative therapy for a range of pri-
mary immunodeficiency syndromes.271
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Introduction: Total body irradiation (TBI) has been considered as
the cornerstone of conditioning for hematopoietic stem cell trans-
plantation (HSCT) in pediatric patients diagnosed with acute lym-
phoblastic leukemia (ALL). However, it involves important late
effects such as growth delay, gonadal and thyroid dysfunction, cata-
racts and secondary cancers.
Material and Methods: We present our results of 127 transplants
performed in 105 children with ALL in our unit with chemother-
apy-based conditioning from 1996 to 2011. Median age was 7 years
(range, 4 months-17 years). There were 91 male and 36 female. Dis-
ease status was 1st CR in 41, 2nd CR in 53 and.2nd CR in 33. Stem
cell source was mainly peripheral blood in 91 patients, 26 cord blood
and in 10 patients was bone marrow. Donor was an identical sibling
in 41, matched and mismatched unrelated donor in 54 and haploi-
dentical in 32 cases. It was the second hematopoietic transplant for
32 patients. All conditioning regimens integrated oral or iv busulfan
combined with cyclophosphamide from 1996 to 2003 andwith iv flu-
darabine/thiotepa since 2004 to 2011. Graft-versus-host disease pro-
phylaxis consisted on cyclosporine 6 methotrexate.
Results: With a median follow-up of 4 years, disease-free-survival
(DFS) was 5165%. The incidence of relapse was 18% and trans-
plant-related-mortality was 34%. Primary or secondary graft failure
was 10%. In multivariate analysis of DFS the only prognostic factor
was disease status at transplant (p\0.002). DFS according disease-
status was 7267% in 1st CR, 4767% in 2ndCR, 3368% in 3rd CR.
Conclusion:Chemotherapy-based conditioning can be used in chil-
dren with ALL with similar outcome than using TBI and reducing
long-term toxicity.
